Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors
Defence Therapeutics (DTCFF) has announced Dr. Elias Theodorou has joined its board of directors. Dr. Theodorou brings over 25 years of experience in cancer research, stem cell differentiation, and gene delivery. He currently serves as Chief Scientific Officer at Protos Biologics Inc. and previously held leadership positions at WBC Biosciences, ATUM Inc., and Metagenomix Inc. The company granted him 100,000 incentive stock options, exercisable at $0.60 per share for three years.
Additionally, Mr. Arnab De has been appointed as CFO and Corporate Secretary, replacing Mr. Joseph Meagher and Miss Carrie Cesarone. The board now consists of five members: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova, and Dr. Elias Theodorou.
Defence Therapeutics (DTCFF) ha annunciato che Dr. Elias Theodorou è entrato a far parte del suo consiglio di amministrazione. Il Dr. Theodorou porta con sé oltre 25 anni di esperienza nella ricerca sul cancro, nella differenziazione delle cellule staminali e nella somministrazione genica. Attualmente ricopre il ruolo di Chief Scientific Officer presso Protos Biologics Inc. e in precedenza ha avuto posizioni di leadership in WBC Biosciences, ATUM Inc. e Metagenomix Inc. L'azienda gli ha concesso 100.000 opzioni su azioni incentivanti, esercitabili a $0.60 per azione per tre anni.
Inoltre, Mr. Arnab De è stato nominato CFO e Segretario Aziendale, sostituendo Mr. Joseph Meagher e Miss Carrie Cesarone. Il consiglio è ora composto da cinque membri: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova e Dr. Elias Theodorou.
Defence Therapeutics (DTCFF) ha anunciado que Dr. Elias Theodorou se ha unido a su junta directiva. El Dr. Theodorou aporta más de 25 años de experiencia en investigación sobre el cáncer, diferenciación de células madre y entrega de genes. Actualmente se desempeña como Director Científico en Protos Biologics Inc. y anteriormente ocupó posiciones de liderazgo en WBC Biosciences, ATUM Inc. y Metagenomix Inc. La compañía le otorgó 100,000 opciones sobre acciones incentivadas, que se pueden ejercer a $0.60 por acción durante tres años.
Además, Mr. Arnab De ha sido nombrado CFO y Secretario Corporativo, reemplazando a Mr. Joseph Meagher y Miss Carrie Cesarone. La junta ahora está compuesta por cinco miembros: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova y Dr. Elias Theodorou.
Defence Therapeutics (DTCFF)는 Dr. Elias Theodorou가 이사회의 일원이 되었다고 발표했습니다. Theodorou 박사는 암 연구, 줄기세포 분화 및 유전자 전달 분야에서 25년 이상의 경험을 가지고 있습니다. 그는 현재 Protos Biologics Inc.의 최고 과학 책임자 역할을 하고 있으며, 이전에는 WBC Biosciences, ATUM Inc. 및 Metagenomix Inc.에서 리더십을 맡았습니다. 회사는 그에게 100,000개의 인센티브 스톡 옵션을 부여하였으며, 이는 3년 동안 주당 $0.60에 행사할 수 있습니다.
또한, Mr. Arnab De가 CFO 및 기업 비서직으로 임명되었으며, Mr. Joseph Meagher와 Miss Carrie Cesarone를 대체합니다. 이사회는 이제 다음 5명의 회원으로 구성됩니다: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova 및 Dr. Elias Theodorou.
Defence Therapeutics (DTCFF) a annoncé que Dr. Elias Theodorou a rejoint son conseil d'administration. Dr. Theodorou apporte plus de 25 ans d'expérience dans la recherche sur le cancer, la différenciation des cellules souches et la délivrance de gènes. Il occupe actuellement le poste de directeur scientifique chez Protos Biologics Inc. et a précédemment occupé des postes de direction chez WBC Biosciences, ATUM Inc. et Metagenomix Inc. La société lui a accordé 100,000 options d'actions incitatives, exerçables à 0,60 $ par action pendant trois ans.
De plus, Mr. Arnab De a été nommé CFO et secrétaire corporate, remplaçant Mr. Joseph Meagher et Miss Carrie Cesarone. Le conseil compte désormais cinq membres : Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova et Dr. Elias Theodorou.
Defence Therapeutics (DTCFF) hat bekannt gegeben, dass Dr. Elias Theodorou dem Vorstand beigetreten ist. Dr. Theodorou bringt über 25 Jahre Erfahrung in der Krebsforschung, der Differenzierung von Stammzellen und der Genabgabe mit. Er ist derzeit Chief Scientific Officer bei Protos Biologics Inc. und hatte zuvor Führungspositionen bei WBC Biosciences, ATUM Inc. und Metagenomix Inc. Das Unternehmen hat ihm 100.000 Anreizaktienoptionen gewährt, die drei Jahre lang zu einem Preis von $0,60 pro Aktie ausgeübt werden können.
Darüber hinaus wurde Mr. Arnab De zum CFO und Unternehmenssekretär ernannt, um Mr. Joseph Meagher und Miss Carrie Cesarone zu ersetzen. Der Vorstand besteht nun aus fünf Mitgliedern: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova und Dr. Elias Theodorou.
- Addition of experienced molecular biology expert with 25+ years in cancer research
- Strengthened board expertise in gene delivery and payload systems
- Enhanced US market presence through Dr. Theodorou's connections
- Corporate restructuring with CFO and Corporate Secretary changes may cause temporary transition challenges
Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Elias Theodorou has joined the board of directors, effective immediately.
Dr. Elias Theodorou, Ph.D., is a molecular biologist with over 25 years of experience in cancer research, stem cell differentiation, and gene delivery. He is the Chief Scientific Officer and co-founder of Protos Biologics Inc., where he has developed innovative DNA delivery systems. Previously, he served as the Director of Research at WBC Biosciences LLC, where he co-invented a method to modify innate immune cells for enhanced anticancer properties.
Dr. Theodorou has held leadership roles at ATUM Inc. and Metagenomix Inc., significantly advancing molecular biology tools and inventing novel methods for drug screening. He earned his Ph.D. from Yale University, focusing on identifying novel drivers of neural differentiation. He has authored numerous publications and holds patents related to gene therapy and protein engineering.
"With his vast experience in gene and payload delivery, we are grateful to welcome Dr. Elias Theodorou on our board of directors. Dr. Theodorou is a strong molecular research scientist who will bring overall guidance for Defence's development, mainly in the USA, due to his extensive knowledge, involvement and leadership roles with successful US biotech companies," mentioned Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics.
"I believe the Accum® technology has a great potential in the ADCs and radiopharmaceuticals applications. I am excited to join Defence Therapeutics on the board of directors, to bring my knowledge and guidance to the Company's development, as well as to be part of its success," mentioned Dr. Elias Theodorou.
The company has granted 100,000 incentive stock options to Dr. Theodorou, in accordance with the terms and conditions of Defence's stock option plan. Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.
The Company would also like to announce that Mr. Arnab De is appointed CFO and Corporate Secretary, and is stepping down from the board of directors, effective immediately, in replacement of Mr. Joseph Meagher (former CFO) and Miss Carrie Cesarone (former Corporate Secretary). The Company would like to thank Mr. Meagher and Miss Cesarone for their valuable contributions. Defence's current board of directors are represented by five board members: Mr. Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova and Dr. Elias Theodorou.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234528
FAQ
What experience does Dr. Elias Theodorou bring to Defence Therapeutics (DTCFF)?
What stock options were granted to Dr. Theodorou by Defence Therapeutics (DTCFF)?
Who are the current board members of Defence Therapeutics (DTCFF)?
What management changes occurred at Defence Therapeutics (DTCFF) in December 2024?
